Abstract: One or more techniques and/or systems are disclosed for a gastrostomy tube having a proximal portion and a distal portion with at least one lumen extending therethrough. The proximal portion includes first, second, and third ports that are each operably coupled to the proximal portion with the first port configured to provide for suction of contents from a patient's stomach, and the third port configured to provide fluid to an inflatable balloon. The distal portion includes a plurality of first openings configured to transport contents to and from the patient's stomach, at least one second opening configured to cooperate with the second port to provide sump-type function, and a curved portion having a gradual bend of approximately 45°-135°. The curved portion directs a distal end of the tube radially outward and away from a longitudinal axis of the tube.

Abstract: A method for spatial resolution enhanced imaging is provided. The method includes determining a target region of a subject being imaged; estimating an achievable spatial resolution; selecting an increased spatial resolution that is greater than a predetermined spatial resolution and equal to or less than the achievable spatial resolution; and acquiring image data of the target region with the increased spatial resolution. A method for enhancing the contrast between the region of interest and other tissue region in the image data acquired with the increased spatial resolution and other tissue region in image data acquired with the predetermined spatial resolution due to the intrinsic partial volume effect is also provided.

Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.

Abstract: Disclosed are methods for making a vascularized hollow organ derived from human intestinal organoid (HIOs). The HIOs may be obtained from human embryonic stem cells (ESC's) and/or induced pluripotent stem cells (iPSCs), such that the HIO forms mature intestinal tissue. Also disclosed are methods for making a human intestinal tissue containing a functional enteric nervous system (ENS).

Abstract: A gastrojejunostomy tube may comprise a jejunal tube, gastric tube, and a balloon tube. The jejunal tube may comprise a port at a proximal end and an opening at a distal end. The gastric tube may comprise a port at a proximal end and an opening at a distal end. The gastric tube may be operably, fixedly coupled with the jejunal tube to form a tubular portion of the gastrojejunostomy tube. The balloon tube may comprise a port at a proximal end and a balloon at a distal end, and may be sized to dispose the balloon in the stomach of the target patient. The balloon tube may be selectably removable from the tubular portion of the gastrojejunostomy tube such that the tubular portion remains in the target patient and the balloon tube is removed from the target patient and replaced by another balloon tube.

Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.

Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by administering to the subject a pharmaceutical composition comprising a kallikrein 5 (KLK5) inhibitor, and a pharmaceutically acceptable carrier.

Abstract: Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof.

Abstract: A method of assessing risk of chronic post-surgical pain (CPSP) in a subject based on genetic factors, non-genetic factors, or a combination thereof. Genetic factors include a genetic profile comprising a combination of single nucleotide polymorphisms (SNPs) in one or more of the specific genes disclosed herein. Non-genetic factors include psychological factors and psychophysical factors. Any of the methods disclosed herein may further comprise applying to the subject a pain management approach based on the subject's risk of developing CPSP.

Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Abstract: The disclosure provides methods for determining whether a sepsis patient is likely to develop severe sepsis associated acute kidney injury (SA-AKI) using a combination of clinical data and biomarker data obtained during the first 24 hours following the subject's diagnosis with sepsis. The methods described here are useful for preventing SA-AKI in at-risk patients as well as for point-of-care clinical decision support and stratifying septic shock patients for clinical trials.

Abstract: Provided herein are methods for preparing hematopoietic stem cells (HSCs) having enhanced engraftment activity, for example, by contacting HSCs in the presence of a p38 MAPK inhibitor and a HIF-1a stabilizer.

Abstract: Some embodiments of the invention include modified cells. Certain embodiments of the invention include methods of using modified cells. Other embodiments of the invention include methods of administering modified cells. Further embodiments of the invention include methods of administering modified cells to treat diseases. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include methods for treating an animal for a disease comprising one or more administrations of one or more compositions comprising (a) a TNF signaling inhibitor, (b) a CD40 inhibitor, a FAS signaling inhibitor, or both, and (c) optionally, a caspase 8 inhibitor. Other embodiments include methods for treating the disease comprising one or h more administrations of one or more compositions comprising (a) the TNF signaling inhibitor and (b) the CD40 inhibitor. Certain embodiments include methods for treating the disease comprising one or more administrations of one or more compositions comprising (a) the TNF signaling inhibitor, (b) the FAS signaling inhibitor, and (c) optionally, the caspase 8 inhibitor. Still other embodiments include methods for treating a human for autoimmune disease, T cell mediated autoimmune disease, IL-1? mediated autoimmune disease, or cytokine release syndrome. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising a myelination enhancing inhibitor to the animal. Other embodiments of the invention include methods for treating an animal for disease or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Still other embodiments of the invention include methods for treating an animal for MS or nerve damage, comprising administration of a composition comprising an HDAC3 inhibitor to the animal. Additional embodiments of the invention are also discussed herein.

Abstract: Methods for alleviating symptoms in a Smith Kingsmore Syndrome (SKS) patient using low doses of a mTOR inhibitor. Also provided herein are methods to determine suitable doses of a mTOR inhibitor for a SKS patient to alleviate at least one symptom associated with SKS with little or no negative impact on behavior features such as the sleep pattern of the SKS patient.

Abstract: A system for objectively analyzing medical image data for the presence of diffuse white matter abnormalities (DWMA) is configured to identify and determine DWMA characteristics that are not visually apparent. As compared to subjective visual diagnosis, objectively determined DWMA characteristics may be automatically compared to each other, and may be compared to and associated with various scales, evaluations, or other assessment criteria used to measure aspects of infant development. As a result, the disclosed system may objectively determine an impact that objectively determined DWMA characteristics will have on one or more developmental scales, which can be expressed as a time deficit, score deficit, or other value indicative of development deficits.

Abstract: A medicinal dosage device may comprise a base having dosing indicators operably connected to the base. The dosing indicators may comprise about four arms spaced at about ninety degree intervals, which may indicate a three hour block of time. The dosing indicators may be selectably movable as a unit relative to the base to indicate medicinal dosage times for at least two different medications.

Abstract: Various aspects of the disclosure relate to a tracheal implant comprising (a) a trachea processed to comprise one or more incisions providing a helical configuration to the processed trachea; and (b) a subject-specific synthetic support.